Analysis of Clinical Characteristics and Prognostic Factors of Patients with Limited-Stage Mantle Cell Lymphoma.
10.19746/j.cnki.issn.1009-2137.2022.04.022
- Author:
Jie SUN
1
;
Sha HE
1
;
Chao RONG
1
;
Hong CEN
1
;
Xiao-Hong TAN
2
Author Information
1. Department of Hematology/Oncology and Pediatric Oncology, Guangxi Medical University Affiliated Tumor Hospital, Nanning 530021， Guangxi Zhuang Autonomous Region, China.
2. Department of Hematology/Oncology and Pediatric Oncology, Guangxi Medical University Affiliated Tumor Hospital, Nanning 530021， Guangxi Zhuang Autonomous Region, China,E-mail:tanxiaohong@gxmu.edu.cn.
- Publication Type:Journal Article
- Keywords:
clinical feature;
limited-stage;
mantle cell lymphoma;
prognosis;
treatment
- MeSH:
Adult;
Aged;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
China;
Female;
Humans;
Ki-67 Antigen/analysis*;
Lymphoma, Mantle-Cell/therapy*;
Male;
Middle Aged;
Prognosis;
Retrospective Studies;
Rituximab/therapeutic use*
- From:
Journal of Experimental Hematology
2022;30(4):1123-1128
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the clinical characteristics, prognostic factors, and treatment outcomes of patients with limited-stage (Ann Arbor stage I or II) mantle cell lymphoma (MCL).
METHODS:Examining consecutive the clinical characteristics, treatment outcomes and prognostic factors of 47 patients with stage I or II MCL diagnosed in Affiliated Tumor Hospital of Guangxi Medical University from January 2005 to June 2020 were analyzed retrospectively.
RESULTS:The median age of patients was 62(37-78) years old. 36 patients were male, accounting for 76.6% of the whole. Among these, 74.5% (n=35) of the diagnoses were estimated at II stage. According to Mantle cell lymphoma International Prognostic Index (MIPI), 28 patients (59.6%) were classified as low risk. Patients who received first-line treatment and could be evaluated received rituximab combined chemotherapy, chemotherapy alone, cytarabine containing chemotherapy or chemotherapy combined with local radiotherapy, the different first-line therapies did not affect the complete response (CR) rate of patients (P＞0.05). The median follow-up time was 81.5 months, the 5-year progression-free survival (PFS) was 37.4% and the 5-year overall survival (OS) rate was 80.6%. Multivariate analysis showed that Ki-67＞30% (P＜0.05) the independent adverse prognostic factor for PFS and OS.
CONCLUSION:Limited-stage MCL is rare. Patients with limited-stage MCL had a better outcome than those with III-IV stage MCL. Patients with limited-stage MCL whose Ki-67≤30% had better PFS and OS.
